|本期目录/Table of Contents|

[1]刘映霞,陈培锦.羧甲司坦联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病稳定期疗效分析[J].慢性病学杂志,2018,(8):1032-1034.
　LIU Ying-xia,CHEN Pei-jin.Efficacy of carbocysteine combined with salmeterol/fluticasone in chronic obstructive pulmonary disease[J].,2018,(8):1032-1034.
点击复制

羧甲司坦联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病稳定期疗效分析(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年8期
页码:
1032-1034
栏目:
论　著
出版日期:
2018-08-31

文章信息/Info

Title:
Efficacy of carbocysteine combined with salmeterol/fluticasone in chronic obstructive pulmonary disease
作者:
刘映霞;  陈培锦
广东省潮州市人民医院重症医学科，广东潮州521000
Author(s):
LIU Ying-xia;  CHEN Pei-jin
Intensive Medicine Department of the People's Hospital of Chaozhou City, Guangdong 521000, China Corresponding author: LIU Ying-xia, E-mail: xuhongc1@126.com
关键词:
慢性阻塞性肺疾病; 羧甲司坦; 沙美特罗/氟替卡松; 肺功能; 慢性阻塞性肺疾病评估测试评分
Keywords:
Chronic obstructive pulmonary disease;  Carbocysteine;  Salmeterol/fluticasone;  Pulmonary function;  COPD assessment test （CAT） score
分类号:
R563
DOI:
-
摘要:
目的探讨羧甲司坦联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病稳定期的疗效及安全性。方法选 取广东省潮州市人民医院2016年5月—2017年12月收治的200例慢性阻塞性肺疾病患者，按照数字表法分为观察 组和对照组，每组100 例。观察组予以羧甲司坦联合沙美特罗/氟替卡松治疗，对照组予以沙美特罗/氟替卡松治 疗，两组治疗6个月后，研究两组患者的慢性阻塞性肺疾病评估测试（CAT） 评分、急性加重次数、肺功能指标 和不良反应发生率。结果6个月疗程后，观察组CAT 评分（13.62±4.21） 分、人均急性加重（0.84±0.51） 次 均低于对照组的（18.52±5.79） 分、（1.46±0.41） 次，差异有统计学意义（P＜0.05）；观察组治疗后第一秒用力 呼气容积（FEV1）（1.14±0.51） L、1秒用力呼气容积占预计值的百分比（FEV1%Pred）（53.87±10.32） %、用 力肺活量（FVC）（3.22±0.52） L 均优于治疗前（P＜0.001），但与对照组比较差异无统计学意义（P＞0.05）。对 照组不良反应率（14.00%） 和观察组（18.00%） 比较，差异无统计学意义（P＞0.05）。结论羧甲司坦片联合 沙美特罗/氟替卡松治疗慢性阻塞性肺疾病可改善患者临床症状，可减少急性加重发生次数，安全可行。
Abstract:
Objective To study the effects and safety of the treatment carbocysteine combined with salmeterol/ fluticasone on patiens with chronic obstructive pulmonary disease （COPD） in stable phase. Methods With number table method, 200 COPD patients from May 2017 to March 2018 were randomly divided into 2 groups: 100 cases in the observation gruop were treated with carbocysteine combined with salmeterol fluticasone and 100 case in the control. The CAT score, the times of acute aggravation, the index of lung function and the incidence of adverse reaction were tested and compared after 6 months of treatment. Results After 6 months of treatment, the CAT score （13.62 ± 4.21） and the times of acute aggravation （0.84±0.51） in the observation group were better than those in the control group （18.52 ± 5.79； 1.46 ± 0.41）（P<0.05） . In the observation group after treatment, FEV1 （1.14±0.51） L, FEV1%Pred （53.87±10.32） %, FVC （3.22±0.52） L were obviously better than those before treatmet （all P<0.05), and there were no differences between the two groups （P>0.05） , There was no significant difference in the adverse reaction rate between the two groups （18.00% vs. 14.00%） . Conclusion The combination of carbocisteine tablets and salmeterol/fluticasone in the treatment of COPD can improve the clinical symptoms and reduce the frequency of acute exacerbation with safety and feasibility.

参考文献/References:


[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺 疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36 (4):255-264.
[2] Pace E, Ferraro M, Siena L, et al. Carbocysteine regulates innate immune responses and senescence processes in cigarette smoke stimulated bronchial epithelial cells [J]. Toxicol Lett, 2013,223(2):198-204.
[3] Song Y, Lu HZ, Xu JR, et al. Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/ GSH-dependent manner [J]. Pharmacol Res,2015(91):98.
[4] Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD[J]. Curr Opin Pharmacol, 2012,12(3):265.
[5] Mansori F, Nemat Khorasani A, Boskabady MH, et al. The effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on management of COPD patients [J]. Clin Respir J, 2010,4(4):241-247.
[6] Latorre M, Novelli F, Vagaggini B, et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/ long- acting beta2- agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS [J]. Pulm Pharmacol Ther, 2015(30): 44-50.
[7] Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate- tosevere COPD and infrequent exacerbations [J]. Respir Med. 2015,109(7):870-881.
[8] Aliba?i? E, Skopljak A, ?engi? A, et al. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life [J]. Med Glas (Zenica), 2017,14(2):182-188.
[9] 徐治波,唐永江,邱婷,等.羧甲司坦联合低剂量沙美特罗/氟替卡 松治疗稳定期中重度慢性阻塞性肺疾病多中心临床研究[J].四川 医学,2011,32(1):4-6.
[10] 杜明辉,孟玉红,魏建.羧甲司坦对老年慢性阻塞性肺疾病患者运 动耐力的影响[J].广东医学,2010,31(10):1346-1347.

备注/Memo

备注/Memo:
作者简介：刘映霞，硕士，主治医师，研究方向：呼吸内科 通信作者：刘映霞，E-mail: xuhongc1@126.com
更新日期/Last Update: 2018-08-30